Hirata, Koichi
Komori, Mika http://orcid.org/0000-0003-1887-1296
Ueda, Kaname http://orcid.org/0000-0003-1967-9829
Zagar, Anthony J.
Kim, Yongin
Jaffe, Dena H. http://orcid.org/0000-0001-5134-037X
Matsumori, Yasuhiko
Takeshima, Takao
Funding for this research was provided by:
Eli Lilly and Company
Eli Lilly Japan
Daiichi-Sankyo
Article History
Accepted: 12 April 2023
First Online: 6 June 2023
Declarations
:
: Conceptualization: MK, KU. Data curation: AJZ, YK, DHJ. Formal analysis: AJZ, YK. Funding acquisition: MK, KU. Investigation: DHJ. Methodology: AJZ, YK, DHJ. Project administration: MK, KU. Resources: DHJ. Software: AJZ, YK. Supervision: KH, YM, TT. Validation: AJZ, YK, DHJ. Visualization: MK, KU. Writing review and editing: MK, KU, DHJ, AJZ, YK, KH, YM, TT. All authors read and approved the final version.
: This study was sponsored by Eli Lilly and Company and operated by Cerner Enviza, an Oracle company (formerly Kantar Health). Medical writing assistance was provided by Koa Webster, Ph.D., and Prudence Stanford, Ph.D., CMPP, of ProScribe—Envision Pharma Group, and was funded by Eli Lilly Japan K.K. and Daiichi Sankyo Company, Limited. ProScribe’s services complied with international guidelines for Good Publication Practice.
: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Koichi Hirata received research funding from the Japan Agency for Medical Research and Development and the Japanese Ministry for Health, Labour and Welfare and personal fees from Amgen Astellas BioPharma K.K.; Daiichi Sankyo Company, Limited; Eisai Co., Ltd.; Eli Lilly Japan K.K.; MSD Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; and Pfizer Japan Inc. Mika Komori and Kaname Ueda are employees of Eli Lilly Japan K.K. and own minor shares in Eli Lilly and Company. Anthony J. Zagar is an employee and minor shareholder of Eli Lilly and Company. At the time of the study, Yongin Kim was an employee and minor shareholder of Eli Lilly and Company. Dena H. Jaffe is an employee of Cerner Enviza, an Oracle company (formerly Kantar Health); Cerner Enviza, an Oracle company, received research funding for this study from Eli Lilly and Company. Yasuhiko Matsumori received personal consultancy fees from Amgen Astellas BioPharma K.K.; Daiichi Sankyo Company, Limited; Eli Lilly Japan K.K.; and Otsuka Pharmaceutical Co., Ltd. Takao Takeshima received personal fees from AbbVie GK; Amgen Astellas BioPharma K.K.; Asahi Kasei Pharma Corporation; Bayer Yakuhin, Ltd; Daiichi Sankyo Company, Limited; Eli Lilly Japan K.K.; Fujifilm Toyama Chemical Co., Ltd.; Janssen Pharmaceutical K.K.; Kowa Company, Ltd.; Kyowa Kirin Co., Ltd.; Lundbeck Japan K.K.; Mitsubishi Tanabe Pharma Corporation; Novartis Pharma K.K.; Ono Pharmaceutical Co., Ltd; Otsuka Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; Sawai Pharmaceutical Co., Ltd.; Sumitomo Dainippon Pharma Co. Ltd.; and UCB Japan Co. Ltd. He also received personal fees from Takeda Pharmaceutical Company Limited outside the submitted work.
: Ethical approval for the study was granted by the Research Institute of Healthcare Data Science Ethical Review Board (ID: RI2020003).
: All survey respondents provided electronic informed consent, and all data were anonymized before analysis.
: Eli Lilly and Company was involved in the study design, data analysis, and preparation of the manuscript. Cerner Enviza, an Oracle company, (formerly Kantar Health) was involved in the study design, data collection, data analysis, and preparation of the manuscript.